Bernard Rudnick, MBA - Managing Partner, Stellar Investment Partners, Founder, Mid Atlantic Bio Angels, Managing Partner, Capgenic Advisors
Bernard C. Rudnick is an investor, founder and managing partner of CapGenic Advisors, LLC, Chief Business Officer of NovoBioPharma, a founder of Mid-Atlantic Bio Angels, investment committee member of Keiretsu Capital, a Managing Partner of Stellar Investment Partners and a member of several additional angel funds or groups. Mr. Rudnick’s entrepreneurial career includes a number of startups, three of which grew to over $60 million in revenue before exiting. He is a founder of one of the nation’s leading entrepreneurial programs (MADV) at the Fox School of Business. He is a director of Otosound, former director and CFO of Immunomic Therapeutics, CFO and director or Atrin Pharmaceuticals, director of Operative Experience. President of Axxia Pharmaceuticals and holds and has held a number of other board positions – both commercial and not-for-profit – throughout his career. With 36 years of experience in executive-level strategy, finance, and management, Mr. Rudnick has senior direct investment, merger & acquisition, capital formation and licensing leadership experience with companies ranging from start-up to Fortune 50. Mr. Rudnick has invested and guided investments in entrepreneurial companies, he has led capital formation and merger transactions totaling over $7 billion. Former advisory and investment clients have included Mitsui (Mitrix), DuPont (Agri-chemical), McKesson Bioservices (now TMO), Kika Clinical Solutions (now IBM). Stellar Investment Partners, is an office representing two families, Bernard Rudnick Consulting, Inc. and Hummel Family Limited Trust. Stellar’s focus has been Life Science, SaaS and Fashion.